On Thursday, the U.S. Senate Subcommittee on Oceans, Atmosphere, Fisheries and Coast Guard will hold a hearing to weigh the risks and benefits of introducing the product into the U.S. marketplace.
The U.S. Food and Drug Administration (FDA) is currently considering an application by AquaBounty to produce genetically engineered salmon, a proposal that the company contends could significantly impact the seafood industry's ability to increase production.
Dubbed AquAdvantage Salmon, the product includes a gene from chinook salmon, which provides the fish with the potential to grow to market size in half the time of conventional salmon.
